Citigroup Maintains Neutral on Hims & Hers Health, Lowers Price Target to $33
Citigroup analyst Daniel Grosslight maintains Hims & Hers Health (NYSE: HIMS ) with a Neutral and lowers the price target from $35 to $33.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.